William Szczepaniak
Director of Business Development at Sequence2Script Inc.
William Szczepaniak
Director of Business Development at Sequence2Script Inc.
Calgary, Alberta
Overview
Work Experience
Director of Business Development
2023 - Current
Principal
2022 - 2023
Director, UCeed Health and Life Science Funds
2022 - 2022
Fund Manager, UCeed Health
2020 - 2022
Director, Economic Development Life Sciences Innovation Hub
2020 - 2022
Management Consultant
2014 - 2020
Provide product management, business development, and technology transfer consulting services to a broad range of medical device companies, healthcare service providers, and individual academic faculty inventors.
Product Manager, Intraoperative Monitoring
2012 - 2014
Directed all global upstream- and downstream- product management and business development activities for the leading producer of intraoperative neurophysiological monitoring (IONM) medical devices.
Laboratory Manager / Research Associate
2005 - 2012
Designed, built, and managed all operational aspects of a startup research laboratory to study pulmonary vascular physiology and clinically translatable animals models of human lung disease.
Senior Associate Consultant
2004 - 2005
Served as a trusted intellectual property (IP) strategy consultant to Fortune 100, 500, mid-size and growth-stage companies.
Senior Licensing Manager
2002 - 2004
Recruited as a senior member of a core startup team to form the first fully staffed and funded technology transfer office at major research university with an annual research budget of nearly $300M
Adjunct Professor
2002 - 2004
Codeveloped and co-taught an upper-level law school elective course entitled, "Biotechnology Law and Policy" for two consecutive years.
Licensing Officer, Technology Transfer Office
2000 - 2002
First person hired in the CMU Technology Transfer Office to specialize in the commercialization of biotechnology, medical device, and life science technologies.
Director of Technology Development
1999 - 2000
Played key technical and business roles as one of the earliest members of a biotechnology startup company.